Literature DB >> 6661617

A subcortico-cortical cholinergic system is affected in Parkinson's disease.

B Dubois, M Ruberg, F Javoy-Agid, A Ploska, Y Agid.   

Abstract

CAT activity was decreased in the frontal cortex and the substantia innominata of parkinsonian subjects, post-mortem. The decrease was greater in the frontal cortex of parkinsonians with dementia. The density of muscarinic cholinergic receptors increased in the cortex. This increase was inversely correlated with tremor. The effects on these parameters of both neuronal degeneration and anticholinergic therapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6661617     DOI: 10.1016/0006-8993(83)90096-3

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  30 in total

1.  The cortical cholinergic system contributes to the top-down control of distraction: Evidence from patients with Parkinson's disease.

Authors:  Kamin Kim; Martijn L T M Müller; Nicolaas I Bohnen; Martin Sarter; Cindy Lustig
Journal:  Neuroimage       Date:  2017-12-19       Impact factor: 6.556

2.  Cognitive effects of scopolamine in dementia.

Authors:  J M Rabey; M Y Neufeld; T A Treves; P Sifris; A D Korczyn
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Dementia in idiopathic Parkinson's disease. Variables associated with its occurrence in 203 patients.

Authors:  T S Elizan; H Sroka; H Maker; H Smith; M D Yahr
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

4.  Dementia in idiopathic Parkinson's disease. A neuropathological study of 32 cases.

Authors:  P Gaspar; F Gray
Journal:  Acta Neuropathol       Date:  1984       Impact factor: 17.088

5.  Cortical vasoactive intestinal peptide in relation to dementia in Parkinson's disease.

Authors:  S Jegou; F Javoy-Agid; C Delbende; M Ruberg; H Vaudry; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-08       Impact factor: 10.154

6.  Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions?

Authors:  B Pillon; B Dubois; G Cusimano; A M Bonnet; F Lhermitte; Y Agid
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

7.  Technetium-99m hexamethylpropylene amine oxime single photon emission tomography of the brain in early Parkinson's disease: correlation with dementia and lateralization.

Authors:  S J Wang; R S Liu; H C Liu; K N Lin; D E Shan; K K Liao; J L Fuh; L S Lee
Journal:  Eur J Nucl Med       Date:  1993-04

8.  Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.

Authors:  M Asahina; T Suhara; H Shinotoh; O Inoue; K Suzuki; T Hattori
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

9.  Substantia innominata: MR findings in Parkinson's disease.

Authors:  Hirobumi Oikawa; Makoto Sasaki; Shigeru Ehara; Takashi Abe
Journal:  Neuroradiology       Date:  2004-10       Impact factor: 2.804

10.  Acetylcholine synthesis in human CSF: implications for study of central cholinergic metabolism.

Authors:  S T DeKosky; S W Scheff; C G Hackney
Journal:  Neurochem Res       Date:  1989-02       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.